Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey
Resumen: Objectives: To evaluate the correlation of O-antigen serotypes with resistance profiles and high-risk clones in a Spanish nationwide survey.
Methods: Up to 30 consecutive healthcare-associated Pseudomonas aeruginosa isolates were collected during October 2017 from each of 51 hospitals (covering all Spanish regions) with a total of 1445 isolates studied. MICs of 13 antipseudomonal agents and MDR/XDR profiles had been previously determined, as well as whole-genome sequences of 185 representative XDR isolates. O-antigen serotypes (O1–O16) were determined by agglutination using serotype-specific antisera (BioRad). The Pseudomonas aeruginosa serotyper (PAst) program was used for in silico serotyping.
Results: The most frequent serotypes were O6 (17.8%), O1 (15.4%) and O11 (13.3%). In contrast, the most frequent serotype among XDR isolates (17.3%) was O4 (34.1%), distantly followed by O11 (15.9%). Within serotypes, XDR phenotypes were more frequent for O12 (60.0%) and O4 (57.3%). The most frequent clone among the XDR isolates was ST175 (40.9%), followed by CC235 (10.7%), ST308 (5.2%) and CC111 (3.6%). Up to 81.6%of XDR ST175 isolates typed O4, whereas 18.4% were non-typeable. O4 genotype was detected in all sequenced (n=55) ST175 isolates. On the other hand, CC235 and ST308 were associated with O11, whereas CC111 was linked to serotype O12.
Conclusions: O4 serotype is linked to the MDR/XDR profile of widespread ST175 (typically only susceptible to colistin, amikacin and the novel combinations ceftolozane/tazobactam and ceftazidime/avibactam) and therefore, after local validation, its detection in the microbiology laboratory might be useful for guiding semi-empirical antipseudomonal therapies and infection control measures in Spanish hospitals.

Idioma: Inglés
DOI: 10.1093/jac/dkz346
Año: 2019
Publicado en: The Journal of antimicrobial chemotherapy 74, 11 (2019), 3217-3220
ISSN: 1460-2091

Factor impacto JCR: 5.439 (2019)
Categ. JCR: INFECTIOUS DISEASES rank: 10 / 93 = 0.108 (2019) - Q1 - T1
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 22 / 270 = 0.081 (2019) - Q1 - T1
Categ. JCR: MICROBIOLOGY rank: 24 / 134 = 0.179 (2019) - Q1 - T1

Factor impacto SCIMAGO: 2.23 - Infectious Diseases (Q1) - Pharmacology (medical) (Q1) - Pharmacology (Q1) - Microbiology (medical) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI15-00088
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI18-00076
Financiación: info:eu-repo/grantAgreement/ES/MINECO-FEDER/ISCIII-REIPI-RD16-0016
Tipo y forma: Artículo (PostPrint)
Área (Departamento): Área Microbiología (Dpto. Microb.Med.Pr.,Sal.Públ.)

Derechos Reservados Derechos reservados por el editor de la revista


Exportado de SIDERAL (2020-09-04-08:30:34)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos



 Registro creado el 2020-09-04, última modificación el 2020-09-04


Postprint:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)